Joseph Smith Jr. awarded Huggins Medal from the Society of Urologic Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JOSEPH SMITH JR. received the Huggins Medal from The Society of Urologic Oncology, the society’s highest honor, for his lifetime contributions to treatment for patients with genitourinary neoplasms. Smith is a professor of Urologic Surgery at Vanderbilt University Medical Center.

The Huggins Medal is named after Charles B. Huggins, who was awarded the Nobel Prize for Physiology or Medicine in 1966 in recognition of his work on the hormonal treatment of prostate cancer. It is the second major award for Smith from the SUO, having been awarded the SUO Medal in 2006.

Smith received the medal and presented the Huggins lecture at SUO’s 2015 annual winter meeting in Washington, D.C. He was also recently named the next editor of The Journal of Urology.

Smith performed Vanderbilt’s first robotic surgery in 2003 and has completed more than 7,000 prostatectomies since that time. With Smith, VUMC has established itself as a leader in robotic surgery and indications have extended in urology to radical cystectomy, partial nephrectomy and bladder suspension.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login